IL164016A0 - Azetidine derivatives as ccr-3 receptor antagonists - Google Patents
Azetidine derivatives as ccr-3 receptor antagonistsInfo
- Publication number
- IL164016A0 IL164016A0 IL16401603A IL16401603A IL164016A0 IL 164016 A0 IL164016 A0 IL 164016A0 IL 16401603 A IL16401603 A IL 16401603A IL 16401603 A IL16401603 A IL 16401603A IL 164016 A0 IL164016 A0 IL 164016A0
- Authority
- IL
- Israel
- Prior art keywords
- ccr
- receptor antagonists
- azetidine derivatives
- azetidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0206218A GB0206218D0 (en) | 2002-03-15 | 2002-03-15 | Organic compounds |
| GB0229627A GB0229627D0 (en) | 2002-12-19 | 2002-12-19 | Organic compounds |
| PCT/EP2003/002715 WO2003077907A1 (en) | 2002-03-15 | 2003-03-14 | Azetidine derivatives as ccr-3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164016A0 true IL164016A0 (en) | 2005-12-18 |
Family
ID=28043401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16401603A IL164016A0 (en) | 2002-03-15 | 2003-03-14 | Azetidine derivatives as ccr-3 receptor antagonists |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7288537B2 (es) |
| EP (1) | EP1487435A1 (es) |
| JP (2) | JP4332433B2 (es) |
| KR (1) | KR100706270B1 (es) |
| CN (1) | CN1638761A (es) |
| AR (1) | AR041786A1 (es) |
| AU (1) | AU2003227072B2 (es) |
| BR (1) | BR0308419A (es) |
| CA (1) | CA2479266A1 (es) |
| CO (1) | CO5611125A2 (es) |
| IL (1) | IL164016A0 (es) |
| MX (1) | MXPA04009057A (es) |
| NO (1) | NO20044373L (es) |
| NZ (1) | NZ535082A (es) |
| PL (1) | PL371055A1 (es) |
| RU (1) | RU2314292C2 (es) |
| TW (2) | TW200800167A (es) |
| WO (1) | WO2003077907A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
| US20070021404A1 (en) * | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2534550A1 (en) * | 2003-09-15 | 2005-03-24 | Novartis Ag | 1, 3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases |
| GB0402101D0 (en) * | 2004-01-30 | 2004-03-03 | Novartis Ag | Organic compounds |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| AU2005295167B2 (en) * | 2004-10-20 | 2012-05-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0720389D0 (en) * | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) * | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| JP7355758B2 (ja) | 2018-01-26 | 2023-10-03 | ラプト・セラピューティクス・インコーポレイテッド | ケモカイン受容体調節剤及びその使用 |
| CN110498750B (zh) * | 2019-09-02 | 2021-10-15 | 南通大学 | 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2093456B (en) | 1980-10-08 | 1984-12-05 | Robins Co Inc A H | 1-r1-3-phenozyazetidines |
| US5095014A (en) * | 1990-12-07 | 1992-03-10 | A. H. Robins Company, Incorporated | 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity |
| WO1999004794A1 (en) * | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| GB0019006D0 (en) * | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| GB0117387D0 (en) * | 2001-07-17 | 2001-09-05 | Novartis Ag | Organic compounds |
-
2003
- 2003-03-13 TW TW096115427A patent/TW200800167A/zh unknown
- 2003-03-13 TW TW092105495A patent/TW200305395A/zh unknown
- 2003-03-13 AR ARP030100876A patent/AR041786A1/es not_active Application Discontinuation
- 2003-03-14 PL PL03371055A patent/PL371055A1/xx not_active Application Discontinuation
- 2003-03-14 NZ NZ535082A patent/NZ535082A/en unknown
- 2003-03-14 EP EP03744367A patent/EP1487435A1/en not_active Withdrawn
- 2003-03-14 RU RU2004130487/04A patent/RU2314292C2/ru not_active IP Right Cessation
- 2003-03-14 KR KR1020047013800A patent/KR100706270B1/ko not_active IP Right Cessation
- 2003-03-14 IL IL16401603A patent/IL164016A0/xx unknown
- 2003-03-14 JP JP2003575960A patent/JP4332433B2/ja not_active Expired - Fee Related
- 2003-03-14 US US10/507,139 patent/US7288537B2/en not_active Expired - Fee Related
- 2003-03-14 BR BR0308419-1A patent/BR0308419A/pt not_active IP Right Cessation
- 2003-03-14 AU AU2003227072A patent/AU2003227072B2/en not_active Ceased
- 2003-03-14 MX MXPA04009057A patent/MXPA04009057A/es active IP Right Grant
- 2003-03-14 CN CNA038056488A patent/CN1638761A/zh active Pending
- 2003-03-14 WO PCT/EP2003/002715 patent/WO2003077907A1/en active Application Filing
- 2003-03-14 CA CA002479266A patent/CA2479266A1/en not_active Abandoned
-
2004
- 2004-09-14 CO CO04091228A patent/CO5611125A2/es not_active Application Discontinuation
- 2004-10-14 NO NO20044373A patent/NO20044373L/no not_active Application Discontinuation
-
2008
- 2008-11-27 JP JP2008302924A patent/JP2009102325A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO5611125A2 (es) | 2006-02-28 |
| AU2003227072B2 (en) | 2006-08-10 |
| NZ535082A (en) | 2006-08-31 |
| TW200305395A (en) | 2003-11-01 |
| KR100706270B1 (ko) | 2007-04-11 |
| AR041786A1 (es) | 2005-06-01 |
| WO2003077907A1 (en) | 2003-09-25 |
| JP2005526773A (ja) | 2005-09-08 |
| BR0308419A (pt) | 2005-01-18 |
| JP2009102325A (ja) | 2009-05-14 |
| PL371055A1 (en) | 2005-06-13 |
| RU2004130487A (ru) | 2005-07-10 |
| US7288537B2 (en) | 2007-10-30 |
| EP1487435A1 (en) | 2004-12-22 |
| JP4332433B2 (ja) | 2009-09-16 |
| MXPA04009057A (es) | 2005-01-25 |
| CA2479266A1 (en) | 2003-09-25 |
| TW200800167A (en) | 2008-01-01 |
| RU2314292C2 (ru) | 2008-01-10 |
| CN1638761A (zh) | 2005-07-13 |
| US20050222118A1 (en) | 2005-10-06 |
| KR20040091690A (ko) | 2004-10-28 |
| NO20044373L (no) | 2004-10-14 |
| AU2003227072A1 (en) | 2003-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1073304A1 (en) | Triazole derivatives as tachykinin receptor antagonists | |
| HK1083188A1 (en) | Diaryl ethers as opioid receptor antagonists | |
| AU2003261392A8 (en) | M3muscarinic acetylcholine receptor antagonists | |
| IL165841A0 (en) | Mchir antagonists | |
| EP1553075A4 (en) | LPA Receptor Antagonists | |
| HK1070887A1 (en) | Tricyclic thrombin receptor antagonists | |
| IL174538A0 (en) | Thrombin receptor antagonists | |
| HK1093070A1 (en) | Imidazole derivatives as glutamate receptor antagonists | |
| IL164016A0 (en) | Azetidine derivatives as ccr-3 receptor antagonists | |
| AU2003255501A1 (en) | Cxcr4 receptor antagonists | |
| PL378753A1 (pl) | Antagoniści receptora CCR-3 | |
| AU2003291959A8 (en) | Novel glucagon antagonists | |
| IL163939A0 (en) | Nk1 antagonists | |
| AU2003267088A8 (en) | Chemokine receptor antagonists as therapeutic agents | |
| IL165727A0 (en) | Chemokine antagonists | |
| AU2003300904A8 (en) | Antagonists for human prolactin | |
| AU2003240705A1 (en) | Morpholinylmethylureas ccr-3 receptor antagonists | |
| AU2002347552A1 (en) | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | |
| GB0203412D0 (en) | 5-HT 2B receptor antagonists | |
| SG131946A1 (en) | Ccr3 receptor antagonists | |
| AU2003287219A8 (en) | Il-8 receptor antagonists | |
| PL375263A1 (en) | 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists | |
| PL370821A1 (en) | N-ureido-piperidines as antagonists viii for ccr-3 receptor | |
| PL370367A1 (en) | Ccr-3 receptor antagonists v | |
| IL162534A0 (en) | Novel alkansulfonamides as endotheline antagonists |